Show simple item record
Author | dc.contributor.author | Pavelka, Karel | |
Author | dc.contributor.author | Burgos-Vargas, Ruben | |
Author | dc.contributor.author | Miranda, Pedro | |
Author | dc.contributor.author | Guzman, Renato | |
Author | dc.contributor.author | Yen, Jeng Hsien | |
Author | dc.contributor.author | Izzi, Mustafa Al | |
Author | dc.contributor.author | Szekanecz, Zoltan | |
Author | dc.contributor.author | Tang, Boxiong | |
Author | dc.contributor.author | Szumski, Annette | |
Author | dc.contributor.author | Kotak, Sameer | |
Author | dc.contributor.author | Bananis, Eustratios | |
Author | dc.contributor.author | Koenig, Andrew S. | |
Author | dc.contributor.author | Mahgoub, Ehab Y. | |
Author | dc.contributor.author | Rahman, Mahboob U. | |
Admission date | dc.date.accessioned | 2019-03-15T16:07:50Z | |
Available date | dc.date.available | 2019-03-15T16:07:50Z | |
Publication date | dc.date.issued | 2014 | |
Cita de ítem | dc.identifier.citation | International Journal of Clinical Rheumatology, Volumen 9, Issue 5, 2018, Pages 415-430 | |
Identifier | dc.identifier.issn | 17584280 | |
Identifier | dc.identifier.issn | 17584272 | |
Identifier | dc.identifier.other | 10.2217/ijr.14.27 | |
Identifier | dc.identifier.uri | https://repositorio.uchile.cl/handle/2250/166306 | |
Abstract | dc.description.abstract | © 2014 Future Medicine Ltd.Aims: We compared etanercept 50 mg once weekly (ETN50)/methotrexate versus etanercept 25 mg (ETN25)/methotrexate or biologic-free methotrexate after response to ETN50/methotrexate in moderate rheumatoid arthitis patients from central/eastern Europe, Latin America and Asia.Methods: In a 36-week induction phase, methotrexate-resistant patients received ETN50/methotrexate. In a 52-week, double-blind phase, patients who achieved sustained Disease Activity Score in 28 joints low disease activity (LDA) were randomized to ETN50/methotrexate, ETN25/methotrexate or methotrexate.Results: Sustained Disease Activity Score in 28 joints LDA was achieved in 85% at week 36. LDA was achieved in 83, 81 and 50% with ETN50/methotrexate, ETN25/methotrexate and methotrexate and remission in 66, 61 and 31%, respectively, at week 88 (p < 0.0001).Conclusion: Etanercept/methotrexate therapy for 36 weeks effectively induced response in this moderate rheumatoid arthritis subpopulation. | |
Lenguage | dc.language.iso | en | |
Publisher | dc.publisher | Future Medicine Ltd. | |
Type of license | dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Chile | |
Link to License | dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/cl/ | |
Source | dc.source | International Journal of Clinical Rheumatology | |
Keywords | dc.subject | biologic | |
Keywords | dc.subject | efficacy | |
Keywords | dc.subject | etanercept | |
Keywords | dc.subject | low disease activity | |
Keywords | dc.subject | methotrexate | |
Keywords | dc.subject | moderate rheumatoid arthritis | |
Keywords | dc.subject | remission | |
Título | dc.title | Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia | |
Document type | dc.type | Artículo de revista | |
Cataloguer | uchile.catalogador | SCOPUS | |
Indexation | uchile.index | Artículo de publicación SCOPUS | |
uchile.cosecha | uchile.cosecha | SI | |
Files in this item
- Name:
- item_84913599962.pdf
- Size:
- 2.439Kb
- Format:
- PDF
This item appears in the following Collection(s)
Show simple item record
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile